Newman Yeilding

Summary

Affiliation: Johnson and Johnson Pharmaceutical Research and Development
Country: USA

Publications

  1. doi request reprint Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update
    Newman Yeilding
    Janssen Research and Development, LLC, Spring House, Pennsylvania 19477, USA
    Ann N Y Acad Sci 1263:1-12. 2012
  2. doi request reprint Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives
    Newman Yeilding
    Centocor Research and Development, Inc, Malvern, Pennsylvania 19087, USA
    Ann N Y Acad Sci 1222:30-9. 2011
  3. doi request reprint Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis
    Honghui Zhou
    Pharmacokinetics, Modeling and Simulation, Clinical Pharmacology Sciences, Centocor Research and Development, Inc, Malvern, Pennsylvania 19355, USA
    J Clin Pharmacol 50:257-67. 2010
  4. doi request reprint Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters
    Manjula Reddy
    Department of Oncology Biomarkers, Ortho Biotech, Unit of Centocor R and D, Malvern, PA, USA
    J Dermatol 37:413-25. 2010
  5. doi request reprint Bounded outcome score modeling: application to treating psoriasis with ustekinumab
    Chuanpu Hu
    Pharmacokinetics and Pharmacometrics, Biologics Clinical Pharmacology, Centocor R and D, a division of Johnson and Johnson Pharmaceutical Research and Development, LLC, Parkway, Malvern, PA 19355, USA
    J Pharmacokinet Pharmacodyn 38:497-517. 2011
  6. doi request reprint Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis
    Chuanpu Hu
    Pharmacokinetics and Pharmacometrics, Biologics Clinical Pharmacology, Centocor Research and Development, Inc, 200 Great Valley Parkway, Malvern, PA 19355, USA
    J Pharmacokinet Pharmacodyn 38:237-60. 2011
  7. doi request reprint Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis
    Yaowei Zhu
    Pharmacokinetics, Modeling and Simulation, Clinical Pharmacology Sciences, Centocor Research and Development, Inc, 200 Great Valley Parkway, Malvern, PA 19355, USA
    J Clin Pharmacol 49:162-75. 2009

Collaborators

Detail Information

Publications7

  1. doi request reprint Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives--an update
    Newman Yeilding
    Janssen Research and Development, LLC, Spring House, Pennsylvania 19477, USA
    Ann N Y Acad Sci 1263:1-12. 2012
    ..A Phase 2b trial in Crohn's disease has also been presented,(14) and three phase 3 studies in Crohn's disease are currently in progress...
  2. doi request reprint Development of the IL-12/23 antagonist ustekinumab in psoriasis: past, present, and future perspectives
    Newman Yeilding
    Centocor Research and Development, Inc, Malvern, Pennsylvania 19087, USA
    Ann N Y Acad Sci 1222:30-9. 2011
    ..Ustekinumab also holds promise for other immune-mediated disorders with significant unmet need...
  3. doi request reprint Population-based exposure-efficacy modeling of ustekinumab in patients with moderate to severe plaque psoriasis
    Honghui Zhou
    Pharmacokinetics, Modeling and Simulation, Clinical Pharmacology Sciences, Centocor Research and Development, Inc, Malvern, Pennsylvania 19355, USA
    J Clin Pharmacol 50:257-67. 2010
    ..A robust exposure-response relationship has been confirmed for ustekinumab in psoriasis...
  4. doi request reprint Positive treatment effects of ustekinumab in psoriasis: analysis of lesional and systemic parameters
    Manjula Reddy
    Department of Oncology Biomarkers, Ortho Biotech, Unit of Centocor R and D, Malvern, PA, USA
    J Dermatol 37:413-25. 2010
    ..Ustekinumab improves histological psoriasis measures, with minimal impact on the systemic immune system...
  5. doi request reprint Bounded outcome score modeling: application to treating psoriasis with ustekinumab
    Chuanpu Hu
    Pharmacokinetics and Pharmacometrics, Biologics Clinical Pharmacology, Centocor R and D, a division of Johnson and Johnson Pharmaceutical Research and Development, LLC, Parkway, Malvern, PA 19355, USA
    J Pharmacokinet Pharmacodyn 38:497-517. 2011
    ..An additional transformation further modifying both tails of the standard logit transformation in the original CO approach was shown to be necessary in this application...
  6. doi request reprint Informative dropout modeling of longitudinal ordered categorical data and model validation: application to exposure-response modeling of physician's global assessment score for ustekinumab in patients with psoriasis
    Chuanpu Hu
    Pharmacokinetics and Pharmacometrics, Biologics Clinical Pharmacology, Centocor Research and Development, Inc, 200 Great Valley Parkway, Malvern, PA 19355, USA
    J Pharmacokinet Pharmacodyn 38:237-60. 2011
    ..This longitudinal-dropout model can serve as a basis to support future alternative dosing regimens for ustekinumab in patients with moderate-to-severe plaque psoriasis...
  7. doi request reprint Population pharmacokinetic modeling of ustekinumab, a human monoclonal antibody targeting IL-12/23p40, in patients with moderate to severe plaque psoriasis
    Yaowei Zhu
    Pharmacokinetics, Modeling and Simulation, Clinical Pharmacology Sciences, Centocor Research and Development, Inc, 200 Great Valley Parkway, Malvern, PA 19355, USA
    J Clin Pharmacol 49:162-75. 2009
    ..To fully understand the clinical relevance of these results, the covariate findings need to be evaluated concurrently with the efficacy and safety data...